Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Biondi PaulOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Ausiello Dennis AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Fraser ClaireOwnership Type:Direct OwnershipSecurities:Stock Option (right to buyNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Graves KurtOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Berenson StephenOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Dere Willard HOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Kender Richard NOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Thorell MarellaOwnership Type:Direct OwnershipSecurities:Stock Options (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:700,000Price:--
-
Feb 16, 2024 (filed on Feb 16, 2024)Insider Name:DesRosier ThomasOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-3,939Price:$1.08
-
Feb 16, 2024 (filed on Feb 16, 2024)Insider Name:Shaff Eric D.Ownership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-11,549Price:$1.08
Filings by filing date
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Biondi PaulOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Ausiello Dennis AOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Fraser ClaireOwnership Type:Direct OwnershipSecurities:Stock Option (right to buyNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Graves KurtOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Berenson StephenOwnership Type:Direct OwnershipSecurities:Stock Option (Right to Buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Dere Willard HOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Apr 04, 2024 (filed on Apr 08, 2024)Insider Name:Kender Richard NOwnership Type:Direct OwnershipSecurities:Stock Option (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:60,000Price:--
-
Mar 25, 2024 (filed on Mar 27, 2024)Insider Name:Thorell MarellaOwnership Type:Direct OwnershipSecurities:Stock Options (right to buy)Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:700,000Price:--
-
Feb 15, 2024 (filed on Feb 16, 2024)Insider Name:DesRosier ThomasOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:M - Exercise or conversion exempt under rule 16b-3# or value acquired/disposed of:-10,625Price:--
-
Feb 14, 2024 (filed on Feb 16, 2024)Insider Name:DesRosier ThomasOwnership Type:Direct OwnershipSecurities:Restricted Stock UnitsNature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:35,625Price:--
News
Biz Brief
Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 200 Sidney St CAMBRIDGE MA 02139-4218 |
Tel: | N/A |
Website: | https://www.serestherapeutics.com |
IR: | See website |
Key People | ||
Eric D. Shaff President, Chief Executive Officer, Director | Marella Thorell Chief Financial Officer, Executive Vice President | David S. Ege Executive Vice President, Chief Technology Officer |
Matthew R. Henn Executive Vice President, Chief Scientific Officer | Thomas J. DesRosier Executive Vice President , Chief Legal Officer, Secretary | Lisa von Moltke Executive Vice President, Chief Medical Officer | Teresa L. Young Executive Vice President, Chief Commercial and Strategy Officer |
Business Overview |
Seres Therapeutics, Inc. is a commercial-stage microbiome therapeutics company. It is focused on the development and commercialization of a novel class of biological drugs, which are designed to treat disease by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. Its lead program, VOWST, is to prevent recurrence of Clostridioides difficile infection (CDI) in patients 18 or older following antibacterial treatment for recurrent CDI. Building upon VOWST, it is developing novel microbiome therapeutics, such as SER-155, to specifically target infections and antimicrobial resistance. SER-155, an oral microbiome therapeutic candidate consisting of a consortium of cultivated bacteria, is designed to prevent enteric-derived infections and resulting blood stream infections and induce immune tolerance responses to reduce the incidence of GvHD in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). |
Financial Overview |
For the fiscal year ended 31 December 2023, Seres Therapeutics Inc revenues increased from $7.1M to $126.3M. Net loss decreased 55% to $113.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research and development expenses decrease of 18% to $125.1M (expense), Pre-Opening Expenses decrease of 53% to $4.2M (expense). |
Employees: | 233 as of Jan 1, 2024 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $98.16M as of Dec 31, 2023 |
Annual revenue (TTM): | $126.33M as of Dec 31, 2023 |
EBITDA (TTM): | -$101.74M as of Dec 31, 2023 |
Net annual income (TTM): | -$113.72M as of Dec 31, 2023 |
Free cash flow (TTM): | -$125.33M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 151,009,462 as of Mar 1, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |